Amylyx Pharmaceuticals, Inc. AMLX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Amylyx Pharmaceuticals, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s return on equity?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported return on equity of -63.3% in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s return on equity changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s return on equity increased by 24.0% year-over-year, from -83.2% to -63.3%.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s return on equity?
- Over 2 years (2023 to 2025), Amylyx Pharmaceuticals, Inc.'s return on equity has grown at a 119.9% compound annual growth rate (CAGR), from 12.7% to -61.6%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.